Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 17 of 17 publications.

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.

Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.

Coombs J, McBurney C, Gondek K, Copley-Merriman C. Evidence of patient reported outcomes in labeling for oncology products: evaluation of United States and European labels. Mapi Quality of Life Newsletter. 2002 Oct;29:1-3.

Douillard JY, Skarin A, Baselga J, Natale R, Giaccone G, Maddox A, Heyes AE. Improvement in disease-related symptoms and quality of life (QOL) in patients treated with advanced non-small cell lung cancer (NSCLC) treated with zd1839 in ideal1 and ideal2. Poster presented at the European Society for Medical Oncology; October 2002. Nice, France.

Salerno DF, Copley-Merriman C, Taylor TN, Shinogle J, Schulz RM. A review of functional status measures for workers with upper extremity disorders. Occup Environ Med. 2002 Oct;59(10):664-70.

Njue AI, Prichard RK. Is tubulin linked to ivermectin resistance? Poster presented at the 10th International Congress of Parasitology; August 2002.

Njue AI, Prichard RK. Characterizing two glutamate receptor subunits from the cattle nematode Cooperia oncophora. Poster presented at the 47th Annual Meeting of the American Association of Veterinary Parasitologists; July 2002.

Copley-Merriman K, Pawel J, Shepard F, Kimmel K, Gulyas S, Eckert S. Randomized phase 2 study of the oral histone deacetylase inhibitor ci-994 plus gemcitabine vs. placebo plus gemcitabine in second-line nsclc: health-related quality of life results. Poster presented at the American Society of Clinical Oncology; May 2002. Orlando, FL.

Lewis B, Silberman C, Heyes AE. Side effects of chemotherapy among patients with ovarian cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research 7th Annual International Meeting; May 2002. Washington, DC.

Dennison CR, Leidy NK, Silberman C, Heyes AE. Interpretation of quality of life data from a clinician's point of view: getting to the clinically meaningful change. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.

Rieux C, Carney R, Lupi D, Dkhissi-Benyahya O, Jansen K, Chounlamountri N, Foster RG, Cooper HM. Analysis of immunohistochemical label of Fos protein in the suprachiasmatic nucleus: comparison of different methods of quantification. J Biol Rhythms. 2002 Apr;17(2):121-36. doi: 10.1177/074873002129002410

Leidy NK, Jonas D, Silberman C, Margolis MK, Heyes AE. What does it all mean? Using health-related quality of life data to interpret treatment outcomes. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.

Carney R, Dardis C, Cullen WK, Felipo V, Anwyl R, Rowan MJ. Early spatial memory deficit induced by 2,5-hexanedione in the rat. Toxicol Lett. 2002 Mar 10;128(1-3):107-15. doi: 10.1016/s0378-4274(01)00538-0

Shah S, Sesti AM, Copley-Merriman K, Clark M. Summary of quality of life labeling components in the package inserts. Poster presented at the DIA-QOL Meeting; March 2002.

Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.

Menter A, Gottlieb A, Griffiths C, Mordin MM. Health-related quality of life impact of weekly intravenous or intramuscular alefacept in patients with psoriasis: results from two randomized, placebo-controlled phase III trials. Poster presented at the Annual Meeting of the American Academy of Dermatology; February 2002.

Santanello NC, Baker D, Cappelleri JC, Copley-Merriman K, DeMarinis R, Gagnon JP, Hsuan A, Jackson J, Mahmoud R, Miller D, Morgan M, Osterhaus J, Tilson H, Willke R. Regulatory issues for health-related quality of life—PhRMA Health Outcomes Committee Workshop, 1999. Value Health. 2002 Jan;5(1):14-25.